Serum Bone Markers in Breast Cancer Patients during 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1271-1274

  Kailajärvi, Marita E H ^a   Salminen, Eeva K ^a   Paija, Outi M M ^a   Virtanen, Arja M ^a,b   Leino, Aila E ^a   Irjala, Kerttu A ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

5 fluorouracil; Bone metabolism markers; Breast cancer; Chemotherapy; Cyclophosphamide; Epirubicin

Indexed keywords

25 HYDROXYVITAMIN D; AMITRIPTYLINE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CYCLOPHOSPHAMIDE; DICLOFENAC; EPIRUBICIN; FERROUS GLYCINE SULFATE; FLUOROURACIL; GLYCINE DERIVATIVE; IBUPROFEN; IRON DERIVATIVE; OSTEOCALCIN; PARACETAMOL; PARATHYROID HORMONE; TEMAZEPAM; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFECT; DRUG INDICATION; FEMALE; HUMAN; OSSIFICATION; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDES; VITAMIN D;

EID: 2442432700     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 6: 679-688, 1998.
2. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 6: 976-982, 1988.
3. Coombes RC, Bliss JM, Wils J et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14: 35-45, 1996.
4. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998.
5. Kenny AM, Prestwood KM, Pilbeam CC and Raisz LG: The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80: 3287-3291, 1995.
6. Love RR, Barden HS, Mazess RB, Epstein S and Chappell RJ: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154: 2585-2588, 1994.
7. Ward RL, Morgan G, Dalley D and Kelly PJ: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22: 87-94, 1993.
8. Koizumi M, Matsumoto S, Takahashi S, Yamashita T and Ogata E: Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 24: 15-20, 1999.
9. Neri B, Cecchettin M, Pacini P, Bartalucci S, Gemelli MT and Giorgi F: Osteocalcin as a biological marker in the therapeutic management of breast cancer bone metastases. Cancer Invest 7: 551-555, 1989.
10. Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I and Rubens RD: Biochemical prediction of response of bone metastases to treatment. Br J Cancer 58: 205-210, 1988.
11. Kailajärvi M, Ahokoski O, Virtanen A, Salminen E and Irjala K: Early effects of 5-fluorouracil, epirubicin and cyclophosphamide therapy on common laboratory tests. Anticancer Res 21: 2867-7282, 2001.
12. Thomas MK, Lloyd-Jones DM, Thadhani RI et al: Hypovitaminosis D in medical inpatients. N Engl J Med 338: 777-783, 1998.
13. Guillemant J, Taupin P, Le HT et al: Vitamin D status during puberty in French healthy male adolescents. Osteoporos Int 10: 222-225, 1999.
14. Watts NB: Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 1359-1368, 1999.
15. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A and van Enk A: Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61: 308-310, 1990.
16. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S and Elomaa I: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15: 1341-1347, 1997.
17. Shapiro CL, Manola J and Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306-3311, 2001.
18. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S and Elomaa I: Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 78: 240-245, 1998.
19. Coleman RE, Mashiter G, Fogelman I et al: Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 24: 1211-1217, 1988.
20. Berruti A, Piovesan A, Torta M et al: Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 73: 1581-1587, 1996.
21. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al: Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26: 505-511, 2000.
22. Villareal DT, Civitelli R, Chines A and Avioli LV: Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 72: 628-634, 1991.
23. Lehtonen-Veromaa M, Möttönen T, Irjala K et al: Vitamin D intake is low and hypovitaminosis D common in healthy 9- to 15-year-old Finnish girls. Eur J Clin Nutr 53: 746-751, 1999.
24. Kauppinen-Mäkelin R, Tähtelä R, Löyttyniemi E, Kärkkäinen J and Välimäki MJ: A high prevalence of hypovitaminosis D in Finnish medical in- and outpatients. J Intern Med 249: 559-563, 2001.